|
|
|
 |
News05.02.12Azelon Pharmaceuticals Announces Completion of Phase 2 Trial Studying Nasal Spray Formulation of Teriparatide in Development for Osteoporosis 11.20.11 Azelon Pharmaceuticals secures $4.5 million in Series A financing to support Phase 2 study of nasal spray teriparatide (PTH1-34) for the treatment of osteoporosis |
|
|||||||
|
|
||||||||
 |
|||||||||
 |
|||||||||
